MCM
PACB icon

MAI Capital Management’s Pacific Biosciences PACB Stock Holding History

MAI Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-226
Closed -$299 – 3918
2026
Q1 		$299 Buy
+226
New +$404 ﹤0.01% 4533
2025
Q1 		– Sell
-153
Closed -$280 – 3534
2024
Q4 		$280 Buy
+153
New +$299 ﹤0.01% 3350

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's PACB Position: Q2 2026 in Review

MAI Capital Management sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 226 shares — an estimated $299 sold.

MAI Capital Management first reported a position in PACB in Q4 2024 and held it in 2 quarters. The position peaked at $299 in Q1 2026. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • MAI Capital Management reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 226 Pacific Biosciences shares in Q2 2026, an estimated $299.
  • MAI Capital Management first reported a position in Pacific Biosciences in Q4 2024 and held it in 2 quarters.
  • MAI Capital Management's Pacific Biosciences position peaked at $299 in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.